<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04152694</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00077498</org_study_id>
    <nct_id>NCT04152694</nct_id>
  </id_info>
  <brief_title>Ceftaroline Pharmacokinetics in Continuous Renal Replacement Therapy</brief_title>
  <official_title>Ceftaroline Pharmacokinetics in Critically Ill Patients Receiving Continuous Renal Replacement Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dosing of ceftaroline in patients with chronic kidney disease is defined, but there is no&#xD;
      data on pharmacokinetics and pharmacodynamics of the drug in patients receiving continuous&#xD;
      renal replacement therapy (CRRT). The purpose of this study is to determine pharmacokinetics&#xD;
      and pharmacodynamics of ceftaroline in a critically ill patient population receiving CRRT, in&#xD;
      order to define a dosing recommendation in this population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ceftaroline fosamil is a time-dependent, hydrophilic, bactericidal fifth generation&#xD;
      cephalosporin that was FDA approved in 2010 for community acquired pneumonia and skin and&#xD;
      skin structure infections. Ceftaroline is FDA approved for both Gram-positive and&#xD;
      Gram-negative organisms. Gram-positive organisms covered are Staphylococcus aureus&#xD;
      (methicillin resistant and methicillin sensitive strains), Streptococcus agalactiae,&#xD;
      Streptococcus pneumonia, and Streptococcus pyogenes. Gram-negative coverage includes&#xD;
      Escherichia coli, Haemophilus influenza, Klebsiella pneumonia, and Klebsiella oxytoca. In&#xD;
      order for ceftaroline to exhibit effective bacterial killing, it requires that a certain&#xD;
      percentage of the dosing interval is spent above the MIC.&#xD;
&#xD;
      Dosing of ceftaroline in patients with chronic kidney disease is defined, but there is no&#xD;
      data on pharmacokinetics and pharmacodynamics of the drug in patients receiving continuous&#xD;
      renal replacement therapy (CRRT). The purpose of this study is to determine pharmacokinetics&#xD;
      and pharmacodynamics of ceftaroline in a critically ill patient population receiving CRRT, in&#xD;
      order to define a dosing recommendation in this population. CRRT modes that patients may be&#xD;
      receiving in this trial include: continuous veno-venous hemofiltration (CVVH), continuous&#xD;
      veno-venous hemodialysis (CVVHD), and continuous veno-venous hemodiafiltration (CVVHDF).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 9, 2018</start_date>
  <completion_date type="Actual">September 1, 2020</completion_date>
  <primary_completion_date type="Actual">September 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ceftaroline pharmacokinetics in critically ill patients receiving continuous renal replacement therapy - Half-life</measure>
    <time_frame>1 year</time_frame>
    <description>Ceftaroline elimination half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ceftaroline pharmacokinetics in critically ill patients receiving continuous renal replacement therapy - Clearance</measure>
    <time_frame>1 year</time_frame>
    <description>Ceftaroline clearance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ceftaroline pharmacokinetics in critically ill patients receiving continuous renal replacement therapy - Volume of distribution</measure>
    <time_frame>1 year</time_frame>
    <description>Ceftaroline volume of distribution</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ceftaroline pharmacokinetics in critically ill patients receiving continuous renal replacement therapy - Sieving coefficient</measure>
    <time_frame>1 year</time_frame>
    <description>Continuous renal replacement therapy modality sieving coefficient for ceftaroline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ceftaroline pharmacodynamics in patients receiving continuous renal replacement therapy</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of time ceftaroline levels are above the minimum inhibitory concentration for the most likely pathogen(s)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Infection During Renal Replacement Therapy</condition>
  <condition>Critically Ill</condition>
  <arm_group>
    <arm_group_label>Ceftaroline in CRRT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Ceftaroline levels measured in patients receiving continuous renal replacement therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ceftaroline levels in CRRT</intervention_name>
    <description>Levels of ceftaroline measured in patients receiving CRRT</description>
    <arm_group_label>Ceftaroline in CRRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Admitted to an intensive care unit&#xD;
&#xD;
          -  Receiving CRRT (CVVH, CVVHDF, CVVHD)&#xD;
&#xD;
          -  Receiving ceftaroline&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant patients&#xD;
&#xD;
          -  Burn patients&#xD;
&#xD;
          -  Patients with toxic epidermal necrolysis or Stevens-Johnson syndrome&#xD;
&#xD;
          -  Patients prescribed extended infusion ceftaroline&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mojdeh Heavner</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, Baltimore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 30, 2019</study_first_submitted>
  <study_first_submitted_qc>November 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Mojdeh Heavner</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceftaroline fosamil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

